From the publishers of JADPRO

Metastatic HER2-Positive Breast Cancer Resource Center

Advertisement
FROM THE EDITOR

Welcome to the Metastatic HER2-Positive Breast Cancer Resource Center! Take a look around and find current information, news, literature, and other resources from this area of oncology treatment. We hope this site is helpful to your practice. If you have any feedback or questions, please contact jadpro-editor@broadcastmed.com

Sarah Donahue | UCSF Health

Sarah Donahue, MPH, ANP, AOCNP
Carol Franc Buck Breast Cancer Center
University of California, San Francisco

News & Literature Highlights

Clinical Breast Cancer

Long term follow-up of the randomized MetaspHER study comparing intravenous versus subcutaneous trastuzumab in patients with HER2-positive metastatic breast cancer

ESMO Open

Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure

Scientific Reports

Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression

2023 ASCO Annual Meeting Abstract

Real-world patient characteristics and treatment patterns associated with tucatinib therapy in patients with HER2+ metastatic breast cancer

https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.1014

Efficacy of tucatinib+trastuzumab+capecitabine (TTC) after trastuzumab-deruxtecan (T-DXd) exposure in Her2-positive metastatic breast cancer: A French multicentre retrospective study

2023 ASCO Annual Meeting Abstract

HER2CLIMB-05: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer

2023 ASCO Annual Meeting Abstract

Pertuzumab retreatment in patients with HER2-positive locally advanced/metastatic breast cancer: Overall survival results of a phase III randomized trial (JBCRG-M05: PRECIOUS)

2023 ASCO Annual Meeting Abstract

Pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer and brain metastases: 3-year follow-up results from the phase 2 PERMEATE trial

2023 ASCO Annual Meeting Abstract

An age-specific pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) from DESTINY-Breast01, -02, and -03

JCO Oncology Practice

Real-world perspectives and practices for pneumonitis/interstitial lung disease associated with trastuzumab deruxtecan use in human epidermal growth factor receptor 2–expressing metastatic breast cancer

Advertisement
Advertisement